Dubai Investments acquires stake in Globalpharma for 100% ownership     

Following the acquisition, made through Dubai Investments Industries, the pharmaceuticals company will now be a wholly owned subsidiary of Dubai Investments

  

Dubai: Dubai Investments PJSC [DFM: DIC], the diversified leading company listed on the Dubai Financial Market, today announced the acquisition of an additional 66% stake in Globalpharma. Following the acquisition, made through Dubai Investments Industries, the pharmaceuticals company will now be a wholly owned subsidiary of Dubai Investments.

In 2014, Dubai Investments divested a 66% stake and had continued to hold a minority 34% equity in the subsidiary.

Khalid Bin Kalban, Managing Director and CEO of Dubai Investments PJSC, said: “Our original investment in Globalpharma was well timed and good for the growth of the healthcare sector in the UAE and region. We see the strategic benefit for making this acquisition. It forms part of the Dubai Investments growth strategy, and underscores our commitment to creating more value for our shareholders.

“Our healthcare portfolio includes different stakes in KCH Healthcare LLC, Clemenceau Medical Centre, tie ups with hospital operators such as NMC in Dubai Investments Park and Mirdif Hills. These investments not only achieve key business objectives for Dubai Investments and support the Dubai economy, they also contribute to the wellbeing of the UAE, improve the reputation of Dubai as a hub for world-class medical care and align with the long term plans of the UAE government for sustainability and progress in fields such as health and science.”

Established in 1998 and headquartered in Dubai Investments Park, Globalpharma grew to become a market leader in certain generic medicines with a strong regional footprint. Globalpharma manufactures and markets pharmaceutical products in more than 14 countries across the GCC, Middle East and neighbouring markets.

Globalpharma manufactures and commercializes pharmaceutical products under CGMP (current good manufacturing practice) conditions including antibiotics, cardiovascular, anti-ulcerants, analgesic, NSAIDs (Nonsteroidal anti-inflammatory drugs), food supplements, vitamins, anti-diabetics, respiratory products and anti-histamine formulations.

© Press Release 2019

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases